About Doctor
Dr. Ying Wang is the Director of the Immunotherapy Center at the Institute of Hematology and Blood Diseases Hospital, Tianjin holding a Chief Physician title and serving as a Master’s Supervisor. She specializes in leukemia and lymphoma treatment, particularly cellular immunotherapy like CAR T Cell therapy and molecular targeted therapy. Dr. Wang has led multiple clinical trials on CAR T-cell therapy, bispecific antibodies, and tyrosine kinase inhibitors. She is affiliated with prestigious medical societies and has published extensively.
Dr. Ying Wang serves as a member of the Standing Committee of the Hematology and Oncology Committee of the Chinese Anti-Cancer Association, a member of the Standing Committee of the Leukemia Branch of the Chinese Medical Education Association, a deputy chairman of the Youth Committee of the Hematology and Rehabilitation Committee of the Chinese Rehabilitation Medicine Association, and a member of the Experimental Diagnosis Group of the Hematology Branch of the Chinese Medical Association.
She excels in cellular immunotherapy, molecular targeted therapy, and combination chemotherapy for leukemia. She has overseen numerous clinical trials related to acute and chronic leukemia, encompassing CAR-T cell therapy, antibody therapeutics, tyrosine kinase inhibitors, and molecularly targeted agents in conjunction with chemotherapy.
Master tutor, secretary-general and member of the Hematology and Oncology Committee of the Chinese Anti-Cancer Association, standing member of the Leukemia Branch of the Chinese Medical Education Association, vice chairman of the Youth Committee of the Hematology Rehabilitation Committee of the Chinese Rehabilitation Medicine Association, member of the Experimental Diagnosis Group of the Hematology Branch of the Chinese Medical Association, corresponding editor of the Chinese Journal of Hematology, and GIPAP registered physician.
She is a postdoctoral researcher at the Winship Cancer Institute of Emory University in the United States. Acquired the Certification of Research Physicians (CPI) from the American Association of Clinical Research Professionals (ACRP). Primarily focused on clinical and fundamental research concerning leukemia, with particular expertise in cell immunotherapy and molecular targeted therapy for the disease.
She has overseen several worldwide and national multicenter clinical trials related to chronic myeloid leukemia, acute lymphoblastic leukemia, tyrosine kinase inhibitors, CAR T cell treatment, and CD3CD19 bifunctional antibodies, among others. He has overseen four projects funded by the National Natural Science Foundation, Tianjin Natural Science Foundation, and Union Youth Fund, and has published over 20 publications in SCI and Chinese core journals.
Director Wang Ying has consistently focused on the forefront of cell therapy technology research and its clinical application, especially in the field of CAR-T cell and related technologies, leading to significant advancements in “bottleneck” technologies. As a key member of the team, she received the first prize for Tianjin Science and Technology Progress in 2020 and was designated “Tianjin Jinmen Medical Talent” in 2023.
She has obtained several forms of assistance, including the National Natural Science Foundation and the Tianjin Science and Technology Commission Natural Science Foundation. She oversees several global and national multicenter clinical studies, has published numerous articles in SCI and domestic core journals, and has authored and contributed to the editing of various hematology guidelines and monographs.
She significantly contributed to the evolution of CD19 CAR-T cells with independent intellectual property rights at the institute and facilitated the development and introduction of China’s inaugural independently researched CAR-T cell product (Nakiolunsai), which became the first such product in China for treating relapsed and refractory acute lymphoblastic leukemia. Director Wang Ying emphasized “contributing in dual capacities” and engaged proactively in governmental discussions.
She was consecutively elected as a member of the 6th Jiusan Society Committee of Heping District, Tianjin, a member of the 15th Chinese People’s Political Consultative Conference (CPPCC) of Heping District, Tianjin, a representative of the 18th People’s Congress of Tianjin, and a deputy director of the Medical and Health Committee of the 13th Jiusan Society Committee of Tianjin.
Her initiatives have often secured the second and third honors from the Jiusan Society Tianjin Committee for involvement in governmental matters. She guided the branch to achieve recognition as the advanced grassroots organization of the Jiusan Society Tianjin Committee in 2019, the advanced unit for propaganda and ideological work of the Jiusan Society Tianjin in 2021, and one of the top ten grassroots organizations of the Jiusan Society Tianjin in 2023.
The designation of “Tianjin March 8 Red Flag Bearer” is a comprehensive recognition of her enduring commitment to clinical practice, her audacity in pursuing scientific research, and her adherence to the fundamental principles of medicine, exemplifying the exemplary conduct of female medical researchers in the contemporary era.
Hospital
Specialization
Dr. Ying Wang specializes in hematology, with a focus on leukemia treatment. Her expertise includes cellular immunotherapy, particularly CAR T-cell therapy, as well as molecular targeted therapies and bispecific antibodies.
As the Director of the Immunotherapy Center at the Institute of Hematology and Blood Diseases Hospital, she has led numerous clinical trials advancing innovative treatments. Dr. Wang is also actively involved in medical research and academic contributions.
Procedures Performed
Dr. Ying Wang provides advanced treatments for leukemia, specializing in:
- CAR T-Cell Therapy: A form of cellular immunotherapy for blood cancers.
- Molecular Targeted Therapy: Using drugs that target specific cancer cell markers.
- Bispecific Antibodies: Innovative treatments that bind to both cancer cells and immune cells to enhance the immune response.
She also leads clinical trials and contributes to the development of novel therapies.
